Improving management and outcomes of the Boston type 1 keratoprosthesis: Lessons learned from available evidence

Boston Keratoprosthesis type I (KPro) surgery is a relatively novel treatment for severe corneal blindness in the context of recurrent graft failure and high-risk conditions such as cicatrizing disease, aniridia, herpetic keratitis or chemical burns. Recently, modifications in design, surgical techniques and postoperative management have increased the success rate and popularity of the Boston KPro. Complication rates have decreased substantially in the last decade making the Boston KPro a safe therapeutic alternative to certain corneal pathologies. However, certain comorbidities such as glaucoma and late-onset fungal infections remain a problem. This article will review recent evidence about management and outcomes of the Boston KPro type I.